What question did this study set out to answer?

To assess whether concomitant oral mesalamine compromises the gastrointestinal survival and colonization of the probiotic Escherichia coli Nissle 1917 (EcN) in healthy volunteers.

July 28, 2009Inflammatory Bowel Diseases

Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers

View Full Paper

Ask AI

Bookmark

Authors

TJThai Hoa Joeres-Nguyen-XuanEvangelisches Krankenhaus Kalk SBStephan Karl BoehmEvangelisches Krankenhaus Kalk LJLars JoeresUCB Pharma (Germany)

Discussion

Member takes

Implication

Randomized double-blind trial demonstrates oral mesalamine does not impair gastrointestinal survival of probiotic Escherichia coli Nissle 1917 in healthy adults, supporting potential co-therapy.

Key Points

To assess whether concomitant oral mesalamine compromises the gastrointestinal survival and colonization of the probiotic Escherichia coli Nissle 1917 (EcN) in healthy volunteers.
Prospective, randomized, double-blind, placebo-controlled trial in 48 healthy volunteers receiving an initial 17-day run-in of oral EcN (5–50 × 10⁹ viable bacteria once daily).
Participants with confirmed EcN-positive stool (n = 40) were randomized to 1 week of combination therapy: EcN plus either mesalamine (1500 mg twice daily) or placebo.
Fecal EcN shedding was measured every 2–3 days during treatment and monitored up to 48 weeks post-discontinuation, alongside safety and tolerability evaluations.
During the 7-day combination phase, the proportion of EcN-positive participants ranged from 70% to 80% with mesalamine versus 85% to 95% with placebo, with no statistically significant differences (day 3, P > 0.15; day 5, P > 0.25; day 7, P > 0.076).
At treatment discontinuation, 16 of 20 participants in the mesalamine arm and 15 of 20 in the placebo arm were EcN positive, subsequently declining to 7 of 20 and 4 of 20 by week 12 post-treatment.
No differences were observed between the mesalamine and placebo groups regarding clinical tolerance or safety parameters.

Cite This Study

Joeres-Nguyen-Xuan et al. (2009) studied this question.

synapsesocial.com/papers/6a7da4321ec832c82ccda777 https://doi.org/10.1002/ibd.21042

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial demonstrates oral mesalamine does not impair gastrointestinal survival of probiotic Escherichia coli Nissle 1917 in healthy adults, supporting potential co-therapy.

Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers

Discussion

Member takes

Implication

Key Points

Cite This Study

Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider